Nicotine Replacement Therapy for Vaping Cessation among Mono and Dual Users: A Mixed Methods Prelimi
Thursday, January 19, 2023
Posted by: Natalia Gromov
Palmer
AM, Carpenter MJ, Rojewski AM, Haire K, Baker NL, Toll BA.
Nicotine Replacement
Therapy for Vaping Cessation among Mono and Dual Users: A Mixed Methods
Preliminary Study.
Addict Behav. 2023 Apr;139:107579. doi: 10.1016/j.addbeh.2022.107579. Epub 2022
Dec 14. PMID: 36549102.
Many adults express interest in e-cigarette cessation; however, there are few
empirically tested interventions for quitting vaping. This study seeks to (1)
evaluate reasons for quitting e-cigarettes in treatment-seeking adults, and (2)
assess the feasibility and acceptability of nicotine replacement therapy (NRT)
for e-cigarette cessation. Adult daily e-cigarette users completed qualitative
interviews about quitting e-cigarettes, then were randomized to either 28-day
supply of combination NRT (21 mg patches, 4 mg lozenges) + supportive booklet or
Quitline referral. Primary aims were feasibility (number who enrolled) and
acceptability (NRT use, adverse side effects). Exploratory aims evaluated
abstinence (7-day point-prevalence) at end of treatment. Of the 30 participants
who were enrolled, 50 % (n = 15) were dual users, and 50 % (n = 15) were
mono-vapers, 26.6 % (n = 8) of whom were former smokers. Participants reported
seeking treatment due to health concerns, dependence, stigma, and cost.
Anticipated challenges of quitting vaping were withdrawal, negative mood,
sensorimotor habits, and convenience. Most completed the end of treatment
survey (n = 24; 80 %). Participants who received NRT reported using the patch M
= 10.89 days and lozenges M = 6.39 days, with few days of adverse effects (M =
2.67). At end of treatment, 6/18 (33.3 %; 6 mono and 0 dual users) in the
intervention group reported abstinence from vaping, compared to 0 in the
control group (Fisher = 5.00, p =.057). In conclusion, adults are interested in
quitting e-cigarettes due to negative consequences of use and are willing to
use pharmacotherapy. Future research should confirm these results in a larger
trial, address cigarette smoking in dual users, and aim to disseminate
treatments.
|
|
Email to a Friend